OSTEOARTHRITIS
Hylan injection no different than placebo injection for pain improvement in hip osteoarthritis
Osteoarthritis Cartilage. 2019 Jan;27(1):59-70. doi: 10.1016/j.joca.2018.08.018.357 patients with hip osteoarthritis were randomized to a single intraarticular injection of either hylan G-F 20 or placebo saline. Patients were assessed over 26-week follow-up for outcome on improvement in the first question of the WOMAC Pain subscale (WOMAC A1), response rate on the WOMAC A1 (minimum 2-pt improvement), the WOMAC Pain subscale overall, the WOMAC Function subscale, and the incidence of adverse events. Results at all timepoints to 26 weeks demonstrated no significant differences between groups in any of the aforementioned outcome measures.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
